

Title (en)

Soluble urokinase plasminogen activator receptor (suPAR) as predictive marker for cardiovascular diseases

Title (de)

Löslicher Urokinase-Plasminogen-Aktivator-Rezeptor (suPAR) als Vorhersagemarker für kardiovaskuläre Krankheiten

Title (fr)

Récepteur soluble de l'activateur plasminogène de l'urokinase (suPAR) en tant que marqueur prédictif des maladies cardio-vasculaires

Publication

**EP 2115478 B1 20140122 (EN)**

Application

**EP 07858108 A 20071221**

Priority

- EP 2007064497 W 20071221
- DK PA200601709 A 20061222
- US 87683806 P 20061222
- US 94707407 P 20070629
- DK PA200700956 A 20070629

Abstract (en)

[origin: WO2008077958A2] The invention concerns a marker for low-grade inflammation and metabolic syndrome (MS) and MS-related diseases and/or low-grade inflammation-related diseases such as cardiovascular disease, ischemic heart disease and type 2 diabetes. More particularly it concerns the measurement of the concentration of soluble urokinase plasminogen activator receptor (suPAR) in human biological fluids (sputum, cystic fluid, ascites, serum, plasma, urine) as a tool of diagnosing and/or prognosticating low-grade inflammation and metabolic syndrome and the risk of development of the related diseases such as cancer, cardiovascular disease, ischemic heart disease and type 2 diabetes.

IPC 8 full level

**G01N 33/68** (2006.01)

CPC (source: EP GB US)

**G01N 33/574** (2013.01 - GB); **G01N 33/6893** (2013.01 - EP GB US); **G01N 2333/70596** (2013.01 - EP US); **G01N 2800/04** (2013.01 - US);  
**G01N 2800/52** (2013.01 - US); **G01N 2800/7095** (2013.01 - US)

Citation (examination)

- EUGEN-OLSEN J ET AL: "Circulating soluble urokinase plasminogen activator receptor predicts cancer, cardiovascular disease, diabetes and mortality in the general population", JOURNAL OF INTERNAL MEDICINE, vol. 268, no. 3, September 2010 (2010-09-01), pages 296 - 308, XP055140843, ISSN: 0954-6820, DOI: doi:10.1111/j.1365-2796.2010.02252.x
- MAHONEY TRACEY S ET AL: "Cell adhesion regulates gene expression at translational checkpoints in human myeloid leukocytes", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 98, no. 18, 28 August 2001 (2001-08-28), pages 10284 - 10289, ISSN: 0027-8424
- SCHNEIDER UFFE V ET AL: "The prognostic value of the suPARnostic ELISA in HIV-1 infected individuals is not affected by uPAR promoter polymorphisms.", BMC INFECTIOUS DISEASES 2007 LNKD- PUBMED:18021410, vol. 7, 2007, pages 134, XP021034161, ISSN: 1471-2334

Cited by

WO2017075268A1

Designated contracting state (EPC)

AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

DOCDB simple family (publication)

**WO 2008077958 A2 20080703; WO 2008077958 A3 20090402;** AU 2007337996 A1 20080703; AU 2007337996 B2 20130314;  
CA 2674521 A1 20080703; CA 2674521 C 20220614; CY 1120296 T1 20190710; DK 2115478 T3 20140310; DK 2500730 T3 20180528;  
EP 2115478 A2 20091111; EP 2115478 B1 20140122; EP 2500730 A1 20120919; EP 2500730 B1 20180307; ES 2456043 T3 20140421;  
ES 2670711 T3 20180531; GB 0912351 D0 20090826; GB 2461410 A 20100106; GB 2461410 B 20110629; GB 2461410 C 20180620;  
HU E037758 T2 20180928; LT 2500730 T 20180510; PL 2500730 T3 20180831; PT 2500730 T 20180528; SI 2500730 T1 20180831;  
TR 201807733 T4 20180621; US 2010098705 A1 20100422; US 2014370527 A1 20141218; US 8815519 B2 20140826;  
US 9645157 B2 20170509

DOCDB simple family (application)

**EP 2007064497 W 20071221;** AU 2007337996 A 20071221; CA 2674521 A 20071221; CY 181100576 T 20180529; DK 07858108 T 20071221;  
DK 12164660 T 20071221; EP 07858108 A 20071221; EP 12164660 A 20071221; ES 07858108 T 20071221; ES 12164660 T 20071221;  
GB 0912351 A 20071221; HU E12164660 A 20071221; LT 12164660 T 20071221; PL 12164660 T 20071221; PT 12164660 T 20071221;  
SI 200732027 T 20071221; TR 201807733 T 20071221; US 201414312298 A 20140623; US 52071807 A 20071212